Maxair Asthma Medicine
Maxair inhalers will not be made, dispensed, or sold in the United States in their current form after December 31, 2013. Maxair contains chlorofluorocarbons (CFCs), chemicals that deplete the ozone layer. The U.S. Food and Drug Administration (FDA) has set this final date for the medication in order to comply with the Montreal Protocol on Substances That Deplete the Ozone Layer. The manufacturer of Maxair is working on a reformulated, CFC-free version, although it is not yet clear when that product will be available to consumers.
Maxair® (pirbuterol acetate) is used for preventing and treating airway spasms, which are most common in people with asthma, but can also occur in people with chronic obstructive pulmonary disease (COPD).
Maxair asthma medicine comes in a special inhaler that does not release the medication until you inhale through the mouthpiece. In clinical studies, the drug started working within five minutes, with its effects typically lasting for five hours. Some people use the inhaler only when needed during an asthma attack, while others use it regularly to prevent attacks.
This asthma medicine works by stimulating beta receptors on the muscles around airways. This action causes the muscles to relax, which opens up the airways and allows more air to get into and through the lungs.
(Click Maxair to learn more about the effects of Maxair asthma medicine, for information on how to use the inhaler, and to find out what side effects may occur during treatment.)